SMO Clinplus Co (301257.SZ) Stock Price

SMO Clinplus Co Price

CLOSED
27.89
​
Market closed

Over the last 6 years SMO Clinplus Co grew revenue by 18.6% annually, reaching 842.18 M CNY. Earnings per share have grown at 13.1% per year over the last 6 years. For SMO Clinplus Co, the net margin of 13.0% is up versus 11.5% a few years ago. At today's price the dividend yield works out to roughly 0.60%. The payout ratio is around 12% of earnings. The dividend has grown at 11.4% per year over the past 2 years. The consensus 12-month price target for SMO Clinplus Co is 56.81 CNY, about 103.7% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

SMO Clinplus Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SMO Clinplus Co business model & stock analysis

SMO ClinPlus Co., Ltd. generates revenue by offering site management organization (SMO) services for clinical research and development to pharmaceutical companies, medical device companies, and health-related product developers. The company provides comprehensive services including pre-preparation planning, site start-up, on-site execution, and full-process project management. Its primary clients are domestic and foreign pharmaceutical firms, medical device manufacturers, and health product R&D entities operating in both domestic and international markets. The firm's service model focuses on supporting clinical trials through end-to-end management, targeting companies engaged in drug development and medical device testing. By delivering tailored SMO solutions, SMO ClinPlus serves the needs of clients requiring efficient site management for their clinical research activities. The company's operations span across domestic and overseas markets, serving a broad range of healthcare industry participants.

Frequently asked questions about SMO Clinplus Co

Analysts currently set an average price target of 56.81 CNY for the SMO Clinplus Co stock (median: 56.81 CNY), implying +103.7 % versus the latest price. The consensus is based on 7 analyst ratings.

5 analysts currently rate the SMO Clinplus Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SMO Clinplus Co to generate revenue of 925.00 M CNY and earnings per share of 1.56 CNY.

Converted at the current exchange rate, the SMO Clinplus Co share trades at 3.80 EUR (27.89 CNY).

The expected revenue of SMO Clinplus Co is 925.00 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SMO Clinplus Co is 124.03 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SMO Clinplus Co is currently 17.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SMO Clinplus Co stock.

The price-to-sales ratio (P/S) of SMO Clinplus Co is currently 2.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SMO Clinplus Co stock.

The Eulerpool Quality Score for SMO Clinplus Co is 5/10.

The ISIN of SMO Clinplus Co is CNE100005CP8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of SMO Clinplus Co is 301257.SZ. The ticker symbol is used to trade SMO Clinplus Co shares on the stock exchange.

Fair ValueTerminal
23.71 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
231,495.99 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
May 17, 2022
ISIN
CNE100005CP8
Cusip
Y806UU103
Market capitalization
2.20 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
17.76
P/Ee 2027
15.21
P/S
P/Se
2.40
EV/EBIT
16.40
P/B Ratio
1.74
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.64 %
Dividend
Dividend yield
0.60 %
Est. Dividend Yield
0.57 %
Payout Ratio
12.18 %
Dividend growth Ø5Y
—
Dividend payments per year
2
Dividend paid since
3 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 22, 2026, 3:40 AM

SMO Clinplus Co Peer Group

SMO Clinplus Co FIGI

301257:CH · BBG00XVCGVJ0301257:CS · BBG00XVCGVL7

All fundamentals and in-depth analysis of SMO Clinplus Co

Our stock analysis for SMO Clinplus Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SMO Clinplus Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.